Details of the Drug Combination

General Information of Drug Combination (ID: DCQ9S40)

Drug Combination Name

TEM Altretamine

Indication

Disease Entry	Status	REF
Colon adenocarcinoma	Investigative	[1]

Component Drugs

TEM DMLNFWU

Altretamine DMKLAYG

Small molecular drug

2D MOL

3D MOL

High-throughput Screening Result

Testing Cell Line: COLO 205

Zero Interaction Potency (ZIP) Score: 6.83

Bliss Independence Score: 8.9

Loewe Additivity Score: 3.07

LHighest Single Agent (HSA) Score: 1.5

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of TEM

Disease Entry	ICD 11	Status	REF
Postherpetic neuralgia	1E91.5	Phase 2	[2]

Indication(s) of Altretamine

Disease Entry	ICD 11	Status	REF
Ovarian cancer	2C73	Approved	[3]

Altretamine Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Human Deoxyribonucleic acid (hDNA)	TTUTN1I	NOUNIPROTAC	Breaker	[4]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Astrocytoma	DCYE9HA	SNB-19	Investigative	[5]
Clear cell renal cell carcinoma	DCD6FV5	A498	Investigative	[5]
Renal cell carcinoma	DCN571O	SN12C	Investigative	[5]
Invasive ductal carcinoma	DCYOYF6	HS 578T	Investigative	[1]
Adenocarcinoma	DCTFH1A	HCT116	Investigative	[6]
High grade ovarian serous adenocarcinoma	DC2AWUL	OVCAR-5	Investigative	[6]
Malignant melanoma	DC276NB	LOX IMVI	Investigative	[6]
Minimally invasive lung adenocarcinoma	DC81Q8J	NCI-H322M	Investigative	[6]
Mixed endometrioid and clear cell carcinoma	DC5EWEH	IGROV1	Investigative	[6]
------------------------------------------------------------------------------------


⏷ Show the Full List of 9 DrugCom(s)

References

1	Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
2	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030055)
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7112).
4	Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agen... Cancer Chemother Pharmacol. 2008 Dec;63(1):19-26.
5	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
6	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.